Companies › Cellbion
3 active drug programs in 3 registered trials: 3 Phase 1; Oncology; next expected readout Apr 2029.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Lutetium (177Lu) DGUL Radioactive PSMA-targeting prostate cancer therapeutic | – | Phase 1 | Metastatic Castration-resistant Prostate Cancer (mCRPC) | Apr 2029 |
| Ga-68-NGUL Diagnostic radiopharmaceutical (gallium-68 labeled) | – | Phase 1 | Prostate Cancer | – |
| Lu-177-DGUL Therapeutic radiopharmaceutical (lutetium-177 labeled) | – | Phase 1 | Prostate Cancer | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT05547061 | Lu-177-DGUL | Phase 1 | Prostate Cancer | Oncology | Jul 2025 |
| NCT05547061 | Ga-68-NGUL | Phase 1 | Prostate Cancer | Oncology | Jul 2025 |
| NCT07244393 | Lutetium (177Lu) DGUL | Phase 1 | Metastatic Castration-resistant Prostate Cancer (mCRPC) | Oncology | Apr 2029 |
No annotated target.
–
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.